710322-47-7 Usage
Uses
Used in Pharmaceutical Research:
(5-CyanoMethyl-pyrazin-2-yl)-carbaMic acid tert-butyl ester is used as a key intermediate in the pharmaceutical industry for the synthesis of various drugs and biologically active compounds. Its unique chemical structure allows for the creation of novel molecules with potential therapeutic applications.
Used in Organic Synthesis:
In the field of organic chemistry, (5-CyanoMethyl-pyrazin-2-yl)-carbaMic acid tert-butyl ester serves as a valuable building block for the development of complex organic molecules. Its functional groups can be further modified or reacted to produce a wide range of chemical products with diverse applications.
Used in Drug Development:
(5-CyanoMethyl-pyrazin-2-yl)-carbaMic acid tert-butyl ester is used as a starting material in drug development, where its chemical properties can be exploited to design and synthesize new pharmaceuticals with improved efficacy, safety, and selectivity.
Used in Chemical Research:
(5-CyanoMethyl-pyrazin-2-yl)-carbaMic acid tert-butyl ester is also utilized in academic and industrial chemical research to study various reaction mechanisms, explore new synthetic routes, and develop innovative methodologies in organic chemistry.
Check Digit Verification of cas no
The CAS Registry Mumber 710322-47-7 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 7,1,0,3,2 and 2 respectively; the second part has 2 digits, 4 and 7 respectively.
Calculate Digit Verification of CAS Registry Number 710322-47:
(8*7)+(7*1)+(6*0)+(5*3)+(4*2)+(3*2)+(2*4)+(1*7)=107
107 % 10 = 7
So 710322-47-7 is a valid CAS Registry Number.
710322-47-7Relevant academic research and scientific papers
Aminoheteroaryl benzamides as kinase inhibitors
-
, (2016/02/15)
The present invention provides a compound of Formula (I) or a salt thereof; and therapeutic uses of these compounds. The present invention further provides pharmaceutical compositions comprising these compounds, and compositions comprising these compounds with a therapeutic co-agent.
5-SUBSTITUTED-PYRAZINE OR PYRIDINE GLUCOKINASE ACTIVATORS
-
Page 132 - 133, (2010/02/07)
The present invention provides a compound according to formula (I) where the substituent designations are provided in the specification. Pharmaceutical compositions comprising a compound according to formula (I) are also provided, said compounds being glucokinase activators which are useful in the treatment of type II diabetes.
